• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在胰腺癌小鼠模型中模拟肿瘤动态并预测对化疗、靶向治疗和免疫治疗的反应。

Modeling tumor dynamics and predicting response to chemo-, targeted-, and immune-therapies in a murine model of pancreatic cancer.

作者信息

Vishwanath Krithik, Choi Hoon, Gupta Mamta, Zhou Rong, Sorace Anna G, Yankeelov Thomas E, Lima Ernesto A B F

机构信息

Department of Aerospace Engineering and Engineering Mechanics, The University of Texas at Austin, Austin, Texas, 78712.

Department of Mathematics, The University of Texas at Austin, Austin, Texas, 78712.

出版信息

bioRxiv. 2025 Jan 3:2025.01.03.631015. doi: 10.1101/2025.01.03.631015.

DOI:10.1101/2025.01.03.631015
PMID:39803494
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11722293/
Abstract

We seek to establish a parsimonious mathematical framework for understanding the interaction and dynamics of the response of pancreatic cancer to the NGC triple chemotherapy regimen (mNab-paclitaxel, gemcitabine, and cisplatin), stromal-targeting drugs (calcipotriol and losartan), and an immune checkpoint inhibitor (anti-PD-L1). We developed a set of ordinary differential equations describing changes in tumor size (growth and regression) under the influence of five cocktails of treatments. Model calibration relies on three tumor volume measurements obtained over a 14-day period in a genetically engineered pancreatic cancer model (KrasLSLG12D-Trp53LSLR172H-Pdx1-Cre). Our model reproduces tumor growth in the control and treatment scenarios with an average concordance correlation coefficient (CCC) of 0.99±0.01. We conduct leave-one-out predictions (average CCC=0.74±0.06), mouse-specific predictions (average CCC=0.75±0.02), and hybrid, group-informed, mouse-specific predictions (average CCC=0.85±0.04). The developed mathematical model demonstrates high accuracy in fitting the experimental tumor data and a robust ability to predict tumor response to treatment. This approach has important implications for optimizing combination NGC treatment strategies.

摘要

我们试图建立一个简约的数学框架,以理解胰腺癌对NGC三联化疗方案(mNab-紫杉醇、吉西他滨和顺铂)、基质靶向药物(骨化三醇和氯沙坦)以及免疫检查点抑制剂(抗PD-L1)的反应的相互作用和动态变化。我们开发了一组常微分方程,描述在五种治疗组合影响下肿瘤大小的变化(生长和消退)。模型校准依赖于在一个基因工程胰腺癌模型(KrasLSLG12D-Trp53LSLR172H-Pdx1-Cre)中14天内获得的三次肿瘤体积测量值。我们的模型在对照和治疗场景中重现肿瘤生长,平均一致性相关系数(CCC)为0.99±0.01。我们进行留一法预测(平均CCC = 0.74±0.06)、小鼠特异性预测(平均CCC = 0.75±0.02)以及混合的、群体信息的、小鼠特异性预测(平均CCC = 0.85±0.04)。所开发的数学模型在拟合实验肿瘤数据方面显示出高精度,并且具有预测肿瘤对治疗反应的强大能力。这种方法对优化NGC联合治疗策略具有重要意义。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/fa1c11a78778/nihpp-2025.01.03.631015v1-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/9754af033a06/nihpp-2025.01.03.631015v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/e0b4406ac4d5/nihpp-2025.01.03.631015v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/44cf63608b9c/nihpp-2025.01.03.631015v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/0d5d9281a822/nihpp-2025.01.03.631015v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/5a675de58600/nihpp-2025.01.03.631015v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/17e3a65e5d38/nihpp-2025.01.03.631015v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/af3a839ed62f/nihpp-2025.01.03.631015v1-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/da94403104a6/nihpp-2025.01.03.631015v1-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/b1c5531ccc66/nihpp-2025.01.03.631015v1-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/af17ab2eec6a/nihpp-2025.01.03.631015v1-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/8ef0d722ee8e/nihpp-2025.01.03.631015v1-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/fa1c11a78778/nihpp-2025.01.03.631015v1-f0012.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/9754af033a06/nihpp-2025.01.03.631015v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/e0b4406ac4d5/nihpp-2025.01.03.631015v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/44cf63608b9c/nihpp-2025.01.03.631015v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/0d5d9281a822/nihpp-2025.01.03.631015v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/5a675de58600/nihpp-2025.01.03.631015v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/17e3a65e5d38/nihpp-2025.01.03.631015v1-f0006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/af3a839ed62f/nihpp-2025.01.03.631015v1-f0007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/da94403104a6/nihpp-2025.01.03.631015v1-f0008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/b1c5531ccc66/nihpp-2025.01.03.631015v1-f0009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/af17ab2eec6a/nihpp-2025.01.03.631015v1-f0010.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/8ef0d722ee8e/nihpp-2025.01.03.631015v1-f0011.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33ec/11722293/fa1c11a78778/nihpp-2025.01.03.631015v1-f0012.jpg

相似文献

1
Modeling tumor dynamics and predicting response to chemo-, targeted-, and immune-therapies in a murine model of pancreatic cancer.在胰腺癌小鼠模型中模拟肿瘤动态并预测对化疗、靶向治疗和免疫治疗的反应。
bioRxiv. 2025 Jan 3:2025.01.03.631015. doi: 10.1101/2025.01.03.631015.
2
Predicting response to combination evofosfamide and immunotherapy under hypoxic conditions in murine models of colon cancer.预测缺氧条件下联合依氟鸟氨酸和免疫疗法在结直肠癌小鼠模型中的反应。
Math Biosci Eng. 2023 Sep 15;20(10):17625-17645. doi: 10.3934/mbe.2023783.
3
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.通过数学建模预测人类实体瘤对检查点抑制剂治疗的临床反应。
Elife. 2021 Nov 9;10:e70130. doi: 10.7554/eLife.70130.
4
Predicting resistance and pseudoprogression: are minimalistic immunoediting mathematical models capable of forecasting checkpoint inhibitor treatment outcomes in lung cancer?预测耐药性和假性进展:极简免疫编辑数学模型是否能够预测肺癌患者接受检查点抑制剂治疗的效果?
Math Biosci. 2024 Oct;376:109287. doi: 10.1016/j.mbs.2024.109287. Epub 2024 Aug 31.
5
Neutrophil-mediated fibroblast-tumor cell il-6/stat-3 signaling underlies the association between neutrophil-to-lymphocyte ratio dynamics and chemotherapy response in localized pancreatic cancer: A hybrid clinical-preclinical study.中性粒细胞介导的成纤维细胞-肿瘤细胞 IL-6/STAT3 信号通路是局部胰腺癌中性粒细胞与淋巴细胞比值动态变化与化疗反应相关的基础:一项临床前研究。
Elife. 2022 Sep 15;11:e78921. doi: 10.7554/eLife.78921.
6
mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53LSL-KrasPdx-1-Cre murine models.在Trp53LSL-KrasPdx-1-Cre小鼠模型中,mTOR抑制剂、吉西他滨和PD-L1抗体阻断联合疗法通过代谢重编程和免疫微环境重塑抑制胰腺癌进展。
Cancer Lett. 2023 Feb 1;554:216020. doi: 10.1016/j.canlet.2022.216020. Epub 2022 Nov 25.
7
Adding combination immunotherapy consisting of cancer vaccine, anti-PD-1 and anti-CSF1R antibodies to gemcitabine improves anti-tumor efficacy in murine model of pancreatic ductal adenocarcinoma.在吉西他滨基础上添加由癌症疫苗、抗PD-1和抗CSF1R抗体组成的联合免疫疗法可提高胰腺导管腺癌小鼠模型的抗肿瘤疗效。
Ann Pancreat Cancer. 2019 Dec;2. doi: 10.21037/apc.2019.11.01.
8
Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model.XPO1 抑制剂与吉西他滨-纳布紫杉醇联合在 KPC 胰腺癌细胞模型中的分子分析。
Clin Transl Med. 2023 Dec;13(12):e1513. doi: 10.1002/ctm2.1513.
9
Blockade of LIF and PD-L1 Enhances Chemotherapy in Preclinical PDAC Models.在临床前胰腺癌模型中,抑制白血病抑制因子(LIF)和程序性死亡受体配体1(PD-L1)可增强化疗效果。
Cancers (Basel). 2025 Jan 9;17(2):204. doi: 10.3390/cancers17020204.
10
Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach.从患者来源的异种移植小鼠模型预测接受治疗患者的肿瘤动态:一种基于转化模型的方法。
J Pharmacokinet Pharmacodyn. 2025 Apr 16;52(3):24. doi: 10.1007/s10928-025-09970-x.

本文引用的文献

1
A global sensitivity analysis of a mechanistic model of neoadjuvant chemotherapy for triple negative breast cancer constrained by in vitro and in vivo imaging data.一项受体外和体内成像数据约束的三阴性乳腺癌新辅助化疗机制模型的全局敏感性分析。
Eng Comput. 2024;40(3):1469-1499. doi: 10.1007/s00366-023-01873-0. Epub 2023 Aug 7.
2
A Pilot Study on Patient-specific Computational Forecasting of Prostate Cancer Growth during Active Surveillance Using an Imaging-informed Biomechanistic Model.基于影像组学的生物力学模型对主动监测期间前列腺癌生长进行个体化计算预测的初步研究
Cancer Res Commun. 2024 Mar 1;4(3):617-633. doi: 10.1158/2767-9764.CRC-23-0449.
3
A mathematical model for predicting the spatiotemporal response of breast cancer cells treated with doxorubicin.
用于预测阿霉素处理的乳腺癌细胞时空反应的数学模型。
Cancer Biol Ther. 2024 Dec 31;25(1):2321769. doi: 10.1080/15384047.2024.2321769. Epub 2024 Feb 27.
4
Cancer statistics, 2024.2024年癌症统计数据。
CA Cancer J Clin. 2024 Jan-Feb;74(1):12-49. doi: 10.3322/caac.21820. Epub 2024 Jan 17.
5
Optimizing combination therapy in a murine model of HER2+ breast cancer.优化HER2阳性乳腺癌小鼠模型中的联合治疗。
Comput Methods Appl Mech Eng. 2022 Dec 1;402. Epub 2022 Aug 17.
6
Pancreatic cancer: Advances and challenges.胰腺癌:进展与挑战。
Cell. 2023 Apr 13;186(8):1729-1754. doi: 10.1016/j.cell.2023.02.014.
7
Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.使用基于混合代理的模型来研究局部吉西他滨治疗胰腺癌的疗效。
PLoS Comput Biol. 2023 Jan 17;19(1):e1010104. doi: 10.1371/journal.pcbi.1010104. eCollection 2023 Jan.
8
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma.针对胰腺导管腺癌肿瘤微环境的临床策略
Cancers (Basel). 2022 Aug 30;14(17):4209. doi: 10.3390/cancers14174209.
9
DWI Metrics Differentiating Benign Intraductal Papillary Mucinous Neoplasms from Invasive Pancreatic Cancer: A Study in GEM Models.扩散加权成像指标鉴别胰腺导管内乳头状黏液性肿瘤与胰腺浸润性癌:基因工程小鼠模型研究
Cancers (Basel). 2022 Aug 20;14(16):4017. doi: 10.3390/cancers14164017.
10
MRI-Based Digital Models Forecast Patient-Specific Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.基于 MRI 的数字模型预测三阴性乳腺癌新辅助化疗的患者特异性治疗反应。
Cancer Res. 2022 Sep 16;82(18):3394-3404. doi: 10.1158/0008-5472.CAN-22-1329.